Skip to content


Infectious Agents and Cancer

Open Access

Integrative proteomics and genomics supports a role for interferon gamma in the pathogenesis of Kaposi sarcoma and finds multiple candidate diagnostic proteins for early detection or prevention

  • Lynn Amon1,
  • Jennifer Gross1,
  • Jackson Orem2,
  • Innocent Mutyaba2,
  • Warren Phipps3, 5,
  • Kurt Diem6,
  • Meei-Li Huang6,
  • Lawrence Corey3, 4, 5, 6,
  • Martin McIntosh1 and
  • Corey Casper1, 3, 5, 7, 8Email author
Infectious Agents and Cancer20105(Suppl 1):A42

Published: 11 October 2010


Interferon GammaNormal SkinDiagnostic MarkerEndothelial Cell ProliferationPunch Biopsy


Kaposi sarcoma (KS) is a common and morbid condition among persons with HIV infection. Strategies for preventing KS or designing better treatment regimens would be aided by the identification of biomarkers for development or progression of KS. Due to the vascular and often disseminated nature of KS, proteomic signatures detected from and specific to KS tumors may yield viable candidate diagnostic protein markers and insights into the pathogenesis of KS.


Flash-frozen punch biopsies from cutaneous samples of tumor and normal skin of individuals having epidemic (HIV-positive) or endemic (HIV-negative) KS were profiled using tandem mass spectrometry. Protein data were integrated with previously existing databases relevant for prioritizing diagnostic marker candidates, including plasma proteome data of cancer-free individuals, normal endothelial cells, and microarrays profiling the mRNA of KS, normal skin, KSHV-infected endothelial cells, and uninfected cells.


In a comparison of 13 HIV+ tumor punch biopsies to 5 HIV+ normal samples, 5100 total proteins were identified. We have identified proteins abundant in the majority of tumor samples and absent from normal skin and plasma of cancer-free individuals that may serve as candidate diagnostic markers. Aligning the data with KS tissue expression data produced 72 proteins that were over-abundant in KS samples in both proteomic and transcriptomic datasets. Most notably, a third of those proteins (24 total) are known to interact with interferon gamma (IFNγ) (enrichment p-value<10-8). Gene symbols are shown in Figure 1. This finding is consistent with previous observations on the importance of IFNγ in endothelial cell proliferation and expression in KS tumors. We are currently evaluating these results further, including conducting other experiments intended to compare the KS proteomics signatures that distinguish 6 HIV+ and 6 HIV- KS tumors. Preliminary results from these analyses will be presented as well.
Figure 1

Tumor proteins with direct or indirect relationships to IFNγ.


The combined use of genomic and proteomic interrogation of biopsy material from KS tumors has revealed a large set of proteins that are overexpressed in KS compared to normal skin and provides a set of candidate diagnostic proteins for the prevention or early detection of KS. These data are also useful in exploring hypotheses regarding the pathogenesis of KS and relating those mechanisms to their role in endemic and epidemic disease.



This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at

Authors’ Affiliations

Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA
Uganda Cancer Institute, Kampala, Africa
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, USA
Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, USA
Department of Medicine, University of Washington, Seattle, USA
Department of Laboratory Medicine, University of Washington, Seattle, USA
Department of Epidemiology, University of Washington, Seattle, USA
Department of Global Health, University of Washington, Seattle, USA


© Casper et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.